Silver Book

Silver Book Fact

Development of a neuroprotective drug could potentially reduce disability from stroke by 50%.

Goldman D, Shang B, Bhattacharya J, Garber A, et al. Consequences of Health Trends and Medical Innovation for the Future Elderly: Health and costs of the future elderly. Health Affairs Web Exclusive Collection. 2005; 24(2). https://www.healthaffairs.org/doi/full/10.1377/hlthaff.W5.R5

Reference

Title
Consequences of Health Trends and Medical Innovation for the Future Elderly: Health and costs of the future elderly
Publication
Health Affairs Web Exclusive Collection
Publication Date
2005
Authors
Goldman D, Shang B, Bhattacharya J, Garber A, et al.
Volume & Issue
Volume 24, Issue 2
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • Catheter ablation reduces risk of stroke and death among AFib patients
    Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from…  
  • The development of antioxidants that reduce oxidative damage is underway. One antioxidant that has been found, uric acid, has an even greater protective effect when combined with tPA.  
  • Stroke rates among Afib patients
    In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.  
  • Effectiveness of an oral pharmacologic agent in preventing venous thrombosis
    An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.